New Delhi: Sanofi India has announced the election of Mr Aditya Narayan as the Chairman of the Board of Directors.
“Sanofi is privileged to have Mr Aditya Narayan as Chairman of the Board of Directors”, said Dr Shailesh Ayyangar, Managing Director – Sanofi India Limited. “For over 60 years, Sanofi India has played the role of a committed and responsible company by making world-class medicines accessible in India, and meeting the challenges of our nation’s growing disease burden. Sanofi India welcomes Mr Narayan, with his commendable track record as a corporate leader, to guide it through the emerging complexities in the Indian pharmaceutical environment.”
Commenting on his new role as Chairman of Sanofi India Limited, Mr Aditya Narayan, mentioned, “Sanofi has a superb track record of building strong pharmaceutical brands, several of which are now household names. Its world class manufacturing facilities and ethical marketing practices enjoy a reputation for excellence in serving its growing customers in India and overseas. It is a privilege for me to have been entrusted with the role of the Chairman of the Board of Directors and I look forward to the support of all its stakeholders in discharging my responsibilities.”
Aditya Narayan, 64, has rich experience in industry for over 40 years. He served ICI Limited, now Akzo Nobel India Limited, for about 30 years across diverse functions and businesses. He was its Managing Director during 1996-2003 and then its non-executive Chairman over 2003 – 2010. Over 2005-2009, he was the President and CEO of BHP Billiton India. He has also served on a number of other Boards. Presently, he is an Independent Director of Hindustan Unilever Limited, Linde India Limited and, Chambal Fertilizers and Chemicals Limited.
Sanofi India Limited (SIL) is listed on the BSE Limited and National Stock Exchange of India Limited. The parent company, Sanofi has 60.4% equity stake in this legal entity. The Company’s portfolio includes pharmaceuticals and consumer healthcare products. Within pharmaceuticals, Sanofi India has a strong presence in diabetes, being the only company with a balanced oral and insulin portfolio.
